Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea (SIX: BSLN) secures a US$30m Cresemba milestone payment
Published by Arron Aatkar, PhD

Basilea Pharmaceutica has announced that the continued strong sales of Cresemba (isavuconazole, Basilea’s lead antifungal therapy) has triggered a US$30m milestone payment from Pfizer, its license partner in Europe.

Cresemba is marketed in over 70 countries, including the US, most EU member states and additional countries inside and outside of Europe. According to the latest available market data, total global in-market sales of Cresemba amounted to US$652m in the 12 months between July 2024 and June 2025, representing  27% growth year-on-year.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.